| 1 |
NCT02497807 |
Unknown † |
The Pathophysiology of Tourette Syndrome: a Multimodal Study |
|
|
Observational |
|
- Second Affiliated Hospital, School of Medicine, Zhejiang University
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Amplitude of low frequency fluctuation of BOLD signal in Tourette syndrome and its relation with iron deficiency
- Brain iron levels in Tourette syndrome
|
40 |
All |
6 Years to 12 Years (Child) |
NCT02497807 |
SAHZJU_CCBD_TouretteS |
PTS |
December 2013 |
November 2016 |
April 2017 |
July 15, 2015 |
April 27, 2016 |
|
- Second Affiliated Hospital,Zhejiang University,School of Medicine
Hangzhou, Zhejiang, China
|
| 2 |
NCT02512406 |
Completed |
Sensory Processing in Tourette Syndrome |
|
- Other: The Sensory Profile
- Other: The Adult/Adolescent Sensory Profile
- Other: Children's Yale-Brown Obsessive Compulsive Scale
- (and 3 more...)
|
Observational |
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- The Sensory Profile
- The Adult/Adolescent Sensory Profile
- Children's Yale-Brown Obsessive Compulsive Scale
- (and 2 more...)
|
18 |
All |
6 Years to 18 Years (Child, Adult) |
NCT02512406 |
IRB201400293 |
|
August 2015 |
January 2016 |
June 2, 2016 |
July 30, 2015 |
April 28, 2017 |
|
- UF Center for Movement Disorders and Neurorestoration
Gainesville, Florida, United States
|
| 3 |
NCT03019731 |
Recruiting |
Behavioral Therapy for Tourette Syndrome |
|
- Behavioral: Therapist-directed Behavioral Therapy
- Behavioral: Home-based DVD Therapy
|
Interventional |
Not Applicable |
- Johns Hopkins University
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Tourette Association of America
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Yale Global Tic Severity Scale Total Tic Score (TTS)
- Clinical Global Impressions-Improvement scale (CGI)
|
80 |
All |
7 Years to 13 Years (Child) |
NCT03019731 |
IRB00111766 |
BTTS:HBTA |
September 2016 |
September 2018 |
September 2019 |
January 13, 2017 |
January 13, 2017 |
|
- Johns Hopkins Hospital
Baltimore, Maryland, United States
|
| 4 |
NCT02765178 |
Completed |
Apathy in Tourette Syndrome and Changes in Quality of Life |
|
- Other: Children's Motivation Scale
- Other: Yale Global Tic Severity Scale (YGTSS)
- Other: Studies Depression Scale for Children (CES-DC)
- (and 2 more...)
|
Observational |
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Children's Motivation Scale
- Yale Global Tic Severity Scale (YGTSS)
- Studies Depression Scale for Children (CES-DC)
- Gilles de la Tourette Syndrome Quality Of Life scale
|
38 |
All |
12 Years to 16 Years (Child) |
NCT02765178 |
IRB201500989 |
|
April 2016 |
March 2017 |
April 2017 |
May 6, 2016 |
July 6, 2017 |
|
- UF Center for Movement Disorders and Neurorestoration
Gainesville, Florida, United States
|
| 5 |
NCT02356003 |
Recruiting |
Transcranial Magnetic Stimulation for Children With Tourette's Syndrome |
|
- Device: Low frequency repetitive transcranial magnetic stimulation
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Yale Global Tic Severity Scale
- Glutamate concentration
- Connectivity
|
11 |
Male |
7 Years to 12 Years (Child) |
NCT02356003 |
REB14-1839 |
TICS |
May 2015 |
April 2019 |
April 2020 |
February 4, 2015 |
October 26, 2017 |
|
- University of Calgary
Calgary, Alberta, Canada
|
| 6 |
NCT02674321 |
Completed |
A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS) |
|
|
Interventional |
Phase 1 |
- Auspex Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety
- Change from Baseline in Total Tic Score of the Yale Global Tic Severity Scale (YGTSS)
- Change from Baseline in Impairment Score of the Yale Global Tic Severity Scale (YGTSS)
- (and 3 more...)
|
23 |
All |
12 Years to 18 Years (Child, Adult) |
NCT02674321 |
SD-809-C-17 |
|
July 2014 |
June 2015 |
June 2015 |
February 4, 2016 |
February 4, 2016 |
|
- Teva Investigational Site #101
Houston, Texas, United States
|
| 7 |
NCT02960698 |
Recruiting |
Impulsivity in Tourette Syndrome : Behavioral and Neuroimaging Study |
|
- Other: IRM and comportemental tasks
|
Interventional |
Not Applicable |
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- behavior performance (percentage of correct responses and reaction time)
- BOLD signal of functional MRI scan
|
120 |
All |
18 Years to 65 Years (Adult) |
NCT02960698 |
C16-07
2016-A00936-45 |
COGIT |
October 2016 |
October 2018 |
October 2020 |
November 10, 2016 |
November 10, 2016 |
|
- HARTMANN
Paris, Ile de France, France
|
| 8 |
NCT03247244 |
Recruiting |
Safety and Efficacy of Cannabis in Tourette Syndrome |
|
|
Interventional |
Phase 2 |
- University Health Network, Toronto
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Modified Rush Video-Based Tic Rating Scale
- The Marijuana Effect Expectancy Questionnaire (MEEQ)
|
12 |
All |
18 Years to 65 Years (Adult) |
NCT03247244 |
14-7726 |
|
November 2017 |
September 2018 |
September 2018 |
August 11, 2017 |
October 26, 2017 |
|
- Toronto Western Hospital - Tourette Syndrome Neurodevelopmental Clinic
Toronto, Ontario, Canada
|
| 9 |
NCT02882490 |
Recruiting |
Parent Behavioral Training for Disruptive Behaviors in Tourette Syndrome |
- Tourette Syndrome
- Behavioral Problem
|
- Behavioral: Parent Training
- Other: Supportive Therapy
|
Interventional |
Not Applicable |
- Hospital Clinic of Barcelona
- Spanish Association for Child and Adolescent Psychiatry (AEPNYA)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Home Situations Questionnaire (HSQ)
- Alabama Parenting Questionnaire
- Parent Stress Index-Short Form
- (and 2 more...)
|
42 |
All |
8 Years to 14 Years (Child) |
NCT02882490 |
AEPNYA 2014-2016 |
|
June 2014 |
June 2017 |
June 2017 |
August 29, 2016 |
August 29, 2016 |
|
- Hospital Clinic
Barcelona, Spain
|
| 10 |
NCT02102698 |
Active, not recruiting |
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Yale Global Tic Severity Scale
- Safety
- DuPaul ADHD rating scale-IV
- (and 4 more...)
|
40 |
All |
7 Years to 17 Years (Child) |
NCT02102698 |
PSY302 |
|
March 2014 |
December 2019 |
December 2019 |
April 3, 2014 |
April 5, 2017 |
|
- UCLA
Los Angeles, California, United States - University of South Florida/Rothman Center for Neuropsychiatry
St. Petersburg, Florida, United States - Emory University School Of Medicine
Atlanta, Georgia, United States - (and 8 more...)
|
| 11 |
NCT02253498 |
Not yet recruiting |
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome |
|
- Device: deep brain stimulation (DBS)
|
Interventional |
Early Phase 1 |
- Beijing Pins Medical Co., Ltd
- Beijing Tiantan Hospital
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Modified Rush Video Rating Scale (mRVRS)
- Tourette Syndrome Symptom List (TSSL)
- SF-36
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02253498 |
PINS-009 |
|
December 2016 |
December 2018 |
December 2018 |
October 1, 2014 |
October 14, 2016 |
|
|
| 12 |
NCT02153463 |
Completed |
Activity in Tourette Syndrome |
- Tourette Syndrome
- Persistent Tic Disorder
|
- Behavioral: Physical Activity Counselling
|
Interventional |
Not Applicable |
- Children's Hospital of Eastern Ontario
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Decrease in Yale Global Tic Severity Scale.
- Change in The Gilles de la Tourette Syndrome Quality of Life Scale for children and adolescents
|
14 |
All |
8 Years to 16 Years (Child) |
NCT02153463 |
14/72X |
|
May 2014 |
December 2014 |
December 2014 |
June 3, 2014 |
August 6, 2015 |
|
- Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
|
| 13 |
NCT01817517 |
Recruiting |
Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome |
|
- Device: Medtronic Activa Deep Brain Stimulation System
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline in the Yale Global Tic Severity Scale (YGTSS)
- Incidence of adverse device effects (ADEs).
- Change from baseline in the Yale-Brown Obsessive Compulsive Scale
- Change from baseline in the WHO Adult ADHD Self-Report Scale (ASRS)
|
10 |
All |
15 Years and older (Child, Adult, Senior) |
NCT01817517 |
NA_00073086 |
|
March 2014 |
April 2019 |
April 2020 |
March 25, 2013 |
January 5, 2018 |
|
- The Johns Hopkins Hospital
Baltimore, Maryland, United States
|
| 14 |
NCT01440023 |
Completed |
Developing Cognitive Training for Tourette Syndrome |
- Tourette Syndrome
- Chronic Tic Disorders
|
- Behavioral: Comprehensive Behavioral Intervention for Tics (CBIT)
- Behavioral: Computerized Response Inhibition Training
- Behavioral: Computerized Placebo Cognitive Training
|
Interventional |
Phase 1 |
- University of Wisconsin, Milwaukee
- Tourette Association of America
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in scores on the Yale Global Tic Severity Scale (YGTSS) across baseline, 4-week, 8-week, and 12 week assessments. during and after the treatment from baseline
- Change in scores on the Clinical Global Impression Severity and Improvement (CGI-S and CGI-I) across baseline, 4-week, 8-week, and 12 week assessments.
|
20 |
All |
9 Years to 17 Years (Child) |
NCT01440023 |
TSA-2011-Lee
TSA |
|
August 2011 |
December 2014 |
December 2014 |
September 23, 2011 |
January 15, 2015 |
|
- The Psychology Clinic, University of Wisconsin-Milwaukee
Milwaukee, Wisconsin, United States
|
| 15 |
NCT02403258 |
Recruiting |
The Effect and Safety of Plum-blossom Needle for Tourette Syndrome |
|
- Other: Plum-blossom needle group
- Behavioral: HRT group
|
Interventional |
Not Applicable |
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- change of YGTSS score from baseline at the 12th week
- change of YGTSS score from baseline at other point times
- CGI score
- change of quality of life from baseline
|
60 |
All |
7 Years to 18 Years (Child, Adult) |
NCT02403258 |
2014S298 |
|
January 2015 |
November 2018 |
December 2018 |
March 31, 2015 |
February 22, 2018 |
|
- Guang'an Men Hospital, China Academy of Chinese Medical Sciences
Beijing, Beijing, China
|
| 16 |
NCT02732496 |
Enrolling by invitation |
Computerized Working Memory Training in Children With ADHD and Comorbid Tourette Syndrome |
- Attention-Deficit/Hyperactivity Disorder
- Tourette Syndrome
|
- Behavioral: Targeted Cognitive Training (TCT)
- Other: Youth Appropriate Online Games
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- Louis V. Gerstner III Research Scholar Award
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Spatial Working Memory (SWM) subtest from the Cambridge Neuropsychological Test Automated Battery (CANTAB)
- Spatial Span (SSP) subtest from the Cambridge Neuropsychological Test Automated Battery (CANTAB)
- The Working Memory Index from the Behavior Rating Inventory of Executive Function (BRIEF)
- The Behavioral Regulation Index from the Behavior Rating Inventory of Executive Function (BRIEF)
|
30 |
All |
7 Years to 13 Years (Child) |
NCT02732496 |
2015P002512 |
|
June 2016 |
September 2017 |
September 2017 |
April 8, 2016 |
April 25, 2017 |
|
|
| 17 |
NCT01719523 |
Completed |
Open-Trial of EPI-743 for Adults With Tourette Syndrome |
|
|
Interventional |
Phase 1 |
- Yale University
- Rembrandt Foundation
- Edison Pharmaceuticals Inc
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Yale Global Tic Severity Scale
- Premonitory Urge for Tics Scale
- Yale-Brown Obsessive Compulsive Scale
- (and 5 more...)
|
10 |
All |
18 Years to 65 Years (Adult) |
NCT01719523 |
120100953972412 |
|
October 2012 |
October 2013 |
October 2013 |
November 1, 2012 |
March 5, 2014 |
|
- Yale Child Study Center
New Haven, Connecticut, United States
|
| 18 |
NCT02134080 |
Suspended |
FAAH Inhibitor Trial for Adults With Tourette Syndrome |
|
- Drug: PF-04457845
- Drug: Placebo
|
Interventional |
Phase 2 |
- Yale University
- Tourette Association of America
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Improvement in Tic Severity
- Improvement of Premonitory Urges
- Improvement in Obsessive Compulsive Disorder (OCD) Severity
- (and 7 more...)
|
10 |
All |
18 Years to 60 Years (Adult) |
NCT02134080 |
1403013669 |
|
May 2014 |
May 2017 |
December 2017 |
May 8, 2014 |
March 22, 2016 |
|
- Connecticut Mental Health Center
New Haven, Connecticut, United States
|
| 19 |
NCT02679079 |
Completed |
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome |
|
- Drug: NBI-98854
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Severity of tic symptoms assessed by Yale Global Tic Severity Scale (YGTSS)
- Measurement of body areas affected, frequency and severity of motor and phonic tics assessed by modified Rush Video-based Tic Rating Scale (RTRS)
- Premonitory Urge for Tics Scale (PUTS)
- Overall severity and improvement of Tourette Syndrome with Clinical Global Impression-Tourette Syndrome (CGI-TS)
|
98 |
All |
6 Years to 17 Years (Child) |
NCT02679079 |
NBI-98854-1501 |
|
January 2016 |
March 2017 |
March 2017 |
February 10, 2016 |
October 11, 2017 |
|
- Sun City, Arizona, United States
- Springdale, Arkansas, United States
- Long Beach, California, United States
- (and 41 more...)
|
| 20 |
NCT03452943 |
Recruiting |
Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents. |
|
- Drug: TEV-50717
- Drug: Placebo
|
Interventional |
Phase 2
Phase 3 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS)
- Change in the Tourette Syndrome-Clinical Global Impression (TS-CGI) score
- Change in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) score
- (and 2 more...)
|
100 |
All |
6 Years to 16 Years (Child) |
NCT03452943 |
TV50717-CNS-30046
2016-000622-19 |
ARTISTS |
February 7, 2018 |
April 30, 2019 |
April 30, 2019 |
March 2, 2018 |
March 19, 2018 |
|
- Teva Investigational Site 046-0102
Rochester, New York, United States
|
| 21 |
NCT02581865 |
Completed |
Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome |
|
- Drug: NBI-98854
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Severity of tic symptoms assessed by Yale Global Tic Severity Scale (YGTSS)
- Measurement of body areas affected, frequency and severity of motor and phonic tics assessed by modified Rush Video-based Tic Rating Scale (RTRS)
- Premonitory Urge for Tics Scale (PUTS)
- Overall severity and improvement of Tourette Syndrome with Clinical Global Impression of Change-Tourette Syndrome (CGI-TS)
|
124 |
All |
18 Years to 64 Years (Adult) |
NCT02581865 |
NBI-98854-1505 |
|
October 2015 |
December 2016 |
December 2016 |
October 21, 2015 |
February 21, 2018 |
|
- Long Beach, California, United States
- National City, California, United States
- San Bernardino, California, United States
- (and 27 more...)
|
| 22 |
NCT02056873 |
Recruiting |
Tourette Syndrome Deep Brain Stimulation |
|
- Device: DBS System
- Device: DBS System (RBS Setting)
|
Interventional |
Not Applicable |
- University of Florida
- Medtronic
- National Institutes of Health (NIH)
- National Science Foundation
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Reduction in total tics on the Yale Global Tic Severity Scale (YGTSS) after 6 months as an effect of centromedian (CM) continuous DBS stimulation
- Correlation between increase in gamma oscillations and improvement in TS symptomatology
- Responsive brain stimulation (RBS) as an effective alternative to continuous DBS stimulation
- Reduction in total tics on the YGTSS after 24 months as an effect of centromedian (CM) continuous DBS stimulation
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02056873 |
IRB201300850 -A-N
KL2TR001429
1553482 |
|
May 2014 |
December 2019 |
December 2019 |
February 6, 2014 |
April 5, 2018 |
|
- University of Florida
Gainesville, Florida, United States
|
| 23 |
NCT02112253 |
Unknown † |
Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome |
|
- Device: Deep brain stimulator ventral electrode up to 2 mA
- Device: Deep brain stimulator ventral electrode up to 3 mA
- Device: Deep brain stimulator dorsal electrode up to 2 mA
- (and 2 more...)
|
Interventional |
Phase 1
Phase 2 |
- The University of Western Australia
- Sir Charles Gairdner Hospital
- Australian Neuromuscular Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Yale Global Tic Severity Scale (YGTSS)
- Modified Rush Video Rating Scale and tic counts
- Tourette's syndrome symptom list
- (and 4 more...)
|
10 |
All |
14 Years to 60 Years (Child, Adult) |
NCT02112253 |
2012-120 |
|
March 2013 |
January 2016 |
January 2016 |
April 11, 2014 |
December 31, 2014 |
|
- Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
|
| 24 |
NCT02247206 |
Completed |
VoIP Delivered Behavior Therapy for Tourette Syndrome |
- Tourette Syndrome
- Chronic Tic Disorder
|
- Behavioral: Behavior Therapy for Tics (CBIT)
|
Interventional |
Phase 2 |
- University of Wisconsin, Milwaukee
- National Institute of Mental Health (NIMH)
- University of Utah
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in Yale Global Tic Severity Scale (YGTSS) total tic severity scores at 10 weeks
- Change from baseline on the Clinical Global Impressions-Severity scale at 10 weeks
- Treatment response rate using the Clinical Global Impressions-Improvement scale at 10 weeks
|
20 |
All |
8 Years to 17 Years (Child) |
NCT02247206 |
MIL105611
F31MH096375-01
5F31MH096375-02 |
|
December 2012 |
September 2013 |
November 2013 |
September 23, 2014 |
September 23, 2014 |
|
- University of Wisconsin-Milwaukee Psychology Department
Milwaukee, Wisconsin, United States
|
| 25 |
NCT03444038 |
Enrolling by invitation |
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome |
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency of treatment-emergent adverse events [Safety and Tolerability]
- Severity of tic symptoms assessed by Yale Global Tic Severity Scale (YGTSS)
|
120 |
All |
6 Years to 18 Years (Child, Adult) |
NCT03444038 |
NBI-98854-TS2004 |
|
February 8, 2018 |
June 2019 |
June 2019 |
February 23, 2018 |
April 19, 2018 |
|
- Neurocrine Clinical Site
Anaheim, California, United States - Neurocrine Clinical Site
San Diego, California, United States - Neurocrine Clinical Site
Gulf Breeze, Florida, United States - (and 8 more...)
|
| 26 |
NCT03066193 |
Recruiting |
Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome |
|
- Drug: Dronabinol
- Dietary Supplement: Palmotoyletahnolamide
|
Interventional |
Phase 3 |
- Yale University
- Therapix Biosciences Ltd.
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in Tic Severity
|
18 |
All |
18 Years to 60 Years (Adult) |
NCT03066193 |
1610018525 |
|
February 1, 2017 |
January 2018 |
January 2019 |
February 28, 2017 |
March 3, 2017 |
|
- Yale Child Study Center
New Haven, Connecticut, United States
|
| 27 |
NCT03487783 |
Not yet recruiting
New |
Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome |
|
- Drug: Aripiprazole Oral Solution
- Drug: Placebo Oral Solution
|
Interventional |
Phase 3 |
- Otsuka Beijing Research Institute
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes from Baseline to Week 8 (or endpoint) in YGTSS TTS.
- Percentage change from Baseline to Week 8 (or endpoint) in YGTSS TTS;
- Response rate on TS-CGI Improvement scale
- (and 2 more...)
|
120 |
All |
6 Years to 17 Years (Child) |
NCT03487783 |
031-403-00107 |
|
April 19, 2018 |
July 19, 2019 |
July 19, 2019 |
April 4, 2018 |
April 4, 2018 |
|
|
| 28 |
NCT02217007 |
Completed |
A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome |
|
- Drug: SNC-102 sustained release tablet
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in total tic severity score on the Yale Global Tic Severity Scale at 4 weeks
- Improvement in total tic severity score on the Yale Global Tic Severity Scale at 8 weeks
- Assess safety and tolerability
- (and 5 more...)
|
16 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02217007 |
SNC-102-211 TS |
|
April 2015 |
January 2016 |
February 2016 |
August 15, 2014 |
April 18, 2016 |
|
- Rush University Medical Center
Chicago, Illinois, United States - North Shore University Hospital, Dept. of Psychiatry
Manhasset, New York, United States
|
| 29 |
NCT02256475 |
Completed |
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome |
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Number of participants with adverse events following dosing with NBI-98854
- Area Under Curve (AUC) of NBI-98854 and its metabolites following repeated daily doses of NBI-98854
- Assessment of tic behaviors associated with TS using the Yale Global Tic Severity Scale (YGTSS)
- (and 4 more...)
|
36 |
All |
6 Years to 18 Years (Child, Adult) |
NCT02256475 |
NBI-98854-1403 |
T-FORCE |
September 2014 |
November 2015 |
December 2015 |
October 3, 2014 |
January 7, 2016 |
|
- San Diego, California, United States
- Kissimmee, Florida, United States
- St. Petersburg, Florida, United States
- (and 7 more...)
|
| 30 |
NCT01475383 |
Terminated |
Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome |
|
- Drug: PF-03654746
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Total Tic Score (Yale Global Tic Severity Scale) from baseline (D0) to end of the 3 wk stable dosing phase (D41)(primary). Average of the 2 assessments of Total Tic Score in 3 wk stable dosing phase is secondary. Score 0-50 (50 = severe)
- Change in Tic Symptom Self Report from baseline to end of 3-wk stable dosing phase (primary); average of 2 assessments of TSSR during 3-wk stable dosing phase is 2ndary. Each symptom is scored 0-3; higher score is worse.
- Change in Premonitory Urge for Tic Scale from baseline to end of 3-wk stable dosing phase (primary); average of 2 assessments of PUTS during 3-wk stable dosing phase is 2ndary. Score 9-36; higher score is worse.
- (and 7 more...)
|
1 |
All |
18 Years to 55 Years (Adult) |
NCT01475383 |
A8801035 |
|
April 2012 |
April 2012 |
April 2012 |
November 21, 2011 |
August 1, 2012 |
|
- Pfizer Investigational Site
Manhasset, New York, United States
|
| 31 |
NCT01405859 |
Completed |
MRI Study of Tic Remission in Tourette Syndrome |
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Resting state functional connectivity
- Magnetic resonance spectroscopy
|
21 |
Male |
18 Years to 35 Years (Adult) |
NCT01405859 |
39432 |
|
January 2010 |
June 2012 |
June 2012 |
July 29, 2011 |
May 12, 2016 |
|
- University of Utah
Salt Lake City, Utah, United States
|
| 32 |
NCT01244633 |
Completed
Has Results |
Ecopipam Treatment of Tourette Syndrome |
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Yale Global Tic Severity Score
- Adult Attention Deficit/Hyperactivity Disorder (ADHD) Self-report Symptom Checklist (ASRS)
- Hamilton Depression Scale
- (and 4 more...)
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT01244633 |
PSY301 |
|
October 2010 |
July 2012 |
July 2013 |
November 19, 2010 |
September 29, 2015 |
September 29, 2015 |
- Johns Hopkins University
Baltimore, Maryland, United States - Atlantic Neuroscience Institute Overlook Hospital
Summit, New Jersey, United States - North Shore Hospital
Manhasset, New York, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
| 33 |
NCT03325010 |
Recruiting |
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome |
|
- Drug: Valbenazine
- Drug: Placebo oral capsule
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Severity of tic symptoms assessed by Yale Global Tic Severity Scale (YGTSS)
- Overall improvement of Tourette Syndrome with Clinical Global Impression-Tourette Syndrome (CGI-TS-Improvement)
|
120 |
All |
6 Years to 17 Years (Child) |
NCT03325010 |
NBI-98854-TS2003 |
|
October 5, 2017 |
December 2018 |
December 2018 |
October 30, 2017 |
April 19, 2018 |
|
- Neurocrine Clinical Site
Sun City, Arizona, United States - Neurocrine Clinical Site
Rogers, Arkansas, United States - Neurocrine Clinical Site
Anaheim, California, United States - (and 31 more...)
|
| 34 |
NCT02187679 |
Unknown † |
Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome |
- Tourette Syndrome
- Chronic Vocal Tic
|
- Drug: Abobotulinum toxin A
|
Interventional |
Not Applicable |
- Detroit Clinical Research Center
- Ipsen
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT02187679 |
DCRC-ISP0016888 |
|
January 2014 |
June 2017 |
|
July 11, 2014 |
February 10, 2015 |
|
- Detroit Clinical Research Center
Farmington Hills, Michigan, United States
|
| 35 |
NCT00311909 |
Completed |
Thalamic Deep Brain Stimulation for Tourette Syndrome |
|
- Device: Thalamic deep brain stimulation
|
Interventional |
Phase 2 |
- University Hospitals Cleveland Medical Center
- Medtronic
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- modified Rush Video Rating Scale (mRVRS)
- at defined points including baseline and 3 months
- tic counts (on video recording)
- (and 5 more...)
|
5 |
All |
18 Years and older (Adult, Senior) |
NCT00311909 |
UHC DBS TS |
|
June 2005 |
|
|
April 6, 2006 |
April 6, 2006 |
|
- University Hospitals of Cleveland
Cleveland, Ohio, United States
|
| 36 |
NCT01172288 |
Completed
Has Results |
N-acetylcysteine (NAC) for Children With Tourette Syndrome |
|
- Drug: N-Acetylcysteine (NAC)
- Drug: Placebo
|
Interventional |
Phase 2 |
- Yale University
- American Academy of Child Adolescent Psychiatry.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Improvement in Tic Severity
- Improvement of Premonitory Urges
- Improvement in OCD Severity
- (and 2 more...)
|
31 |
All |
8 Years to 17 Years (Child) |
NCT01172288 |
YCSC1004006637 |
|
July 2010 |
January 2014 |
January 2014 |
July 29, 2010 |
February 10, 2017 |
December 19, 2016 |
- Yale Child Study Center
New Haven, Connecticut, United States
|
| 37 |
NCT00139308 |
Completed |
High Frequency Stimulation of the GPi or Thalamus in Tourette's Syndrome |
|
- Device: high frequency stimulation
|
Interventional |
Phase 1 |
- Groupe Hospitalier Pitie-Salpetriere
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 55 Years (Adult) |
NCT00139308 |
RBM0008 |
|
|
|
|
August 31, 2005 |
August 31, 2005 |
|
- Centre d'Investigation Clinique-Hôpital Pitié-Salpetriere
Paris, France
|
| 38 |
NCT02619084 |
Completed |
Subthalamic Stimulation in Tourette's Syndrome |
- Tourette's Syndrome
- Tourette Syndrome
- Gilles de la Tourette Syndrome
- Tourette Disorder
|
|
Interventional |
Phase 2 |
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Ministry of Health, Italy
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in Yale Global Tic Severity Scale
- Change in Milan Overall Dementia Assessment (MODA)
- Change in brain activity recorded by PET
- (and 8 more...)
|
10 |
All |
18 Years to 60 Years (Adult) |
NCT02619084 |
RF-131
GR-2009-1594645 |
STN-DBSinTS |
December 2011 |
December 2015 |
December 2015 |
December 2, 2015 |
February 23, 2016 |
|
- Fondazione IRCCS Istituto neurologico Carlo Besta
Milan, Italy
|
| 39 |
NCT00368433 |
Completed |
Hypersensitivity in Tourette Syndrome |
|
|
Observational |
|
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
46 |
All |
18 Years to 65 Years (Adult) |
NCT00368433 |
060232
06-N-0232 |
|
August 21, 2006 |
|
May 24, 2011 |
August 24, 2006 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 40 |
NCT01018056 |
Completed
Has Results |
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission |
|
- Drug: D-serine
- Drug: Riluzole
- Drug: Placebo
|
Interventional |
Phase 4 |
- Johns Hopkins University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Change From Baseline to 6-week Scores for The Total Tic Subscale (TTS)
- The Change From Baseline to 6-week Scores for the Yale Global Tic Severity Scale (YGTSS) Total Score.
- The Change From Baseline to 6-week Score for the Clinical Global Impression -Improvement (CGI-I).
- (and 7 more...)
|
39 |
All |
8 Years to 17 Years (Child) |
NCT01018056 |
NA_00023969
R34MH085844 |
|
November 2009 |
September 2013 |
September 2013 |
November 23, 2009 |
January 30, 2018 |
July 1, 2014 |
- Johns Hopkins University
Baltimore, Maryland, United States
|
| 41 |
NCT01133353 |
Withdrawn |
A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome |
|
- Drug: Tetrabenazine MR
- Drug: Placebo
|
Interventional |
Phase 2 |
- Valeant Pharmaceuticals International, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Improvement in total tic score as measured by the Yale Global Tic Severity Score (YGTSS)
- To evaluate the safety and tolerability of tetrabenazine using cognitive measures
- To evaluate the safety and tolerability of tetrabenazine using an assessment of depression
- (and 4 more...)
|
160 |
All |
5 Years to 16 Years (Child) |
NCT01133353 |
BVF-018-201 |
TBZ-MR |
March 2011 |
November 2011 |
December 2011 |
May 28, 2010 |
November 18, 2010 |
|
|
| 42 |
NCT00965211 |
Unknown † |
Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome |
- Tourette's Syndrome
- Obsessive Compulsive Disorder
|
- Device: HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)
|
Interventional |
Not Applicable |
- Shalvata Mental Health Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Yale Global Tic Severity rating Scale (YGTSS)
- Yale-Brown Obsessive Compulsive Disorder Scale (YBOCS)
|
20 |
All |
18 Years to 55 Years (Adult) |
NCT00965211 |
TMS HBDL |
|
September 2009 |
January 2013 |
January 2013 |
August 25, 2009 |
January 5, 2012 |
|
- Shalvata Mental Health Center
Hod Hasharon, Israel - Shalvata Mental Health Center
Hod Hasharon, Israel
|
| 43 |
NCT01647269 |
Completed |
A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome |
|
- Procedure: Bilateral GPi Deep Brain Stimulation
|
Interventional |
Phase 2 |
- University College, London
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Yale Global Tic Severity Scale
- Change in Modified Rush Video Rating scale
- Change in Yale Brown Obsessive Compulsive Scale
- (and 4 more...)
|
15 |
All |
20 Years and older (Adult, Senior) |
NCT01647269 |
UCL 11/0226 |
|
July 2011 |
November 2014 |
November 2014 |
July 23, 2012 |
March 19, 2015 |
|
- UCL Institute of Neurology
London, United Kingdom
|
| 44 |
NCT00952601 |
Terminated |
Pilot Study of the Modified Atkins Diet for Tourette Syndrome |
|
- Dietary Supplement: Modified Atkins diet
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
20 |
All |
12 Years to 65 Years (Child, Adult) |
NCT00952601 |
AtkinsTourette |
|
September 2008 |
July 2010 |
July 2010 |
August 6, 2009 |
July 15, 2010 |
|
- Johns Hopkins Hospital
Baltimore, Maryland, United States
|
| 45 |
NCT00681863 |
Terminated
Has Results |
Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome |
|
- Drug: pramipexole 0.125 mg BID
- Drug: pramipexole 0.0625 mg QD
- Drug: pramipexole 0.125 mg TID
- (and 2 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patients With Adverse Events Leading to Discontinuation of Trial Drug
- Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
- Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
- (and 5 more...)
|
45 |
All |
6 Years to 17 Years (Child) |
NCT00681863 |
248.642
2008-000342-32 |
|
May 2008 |
October 2009 |
|
May 21, 2008 |
May 23, 2014 |
December 17, 2010 |
- 248.642.0026 Boehringer Ingelheim Investigational Site
Bradenton, Florida, United States - 248.642.0025 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States - 248.642.0006 Boehringer Ingelheim Investigational Site
Columbus, Georgia, United States - (and 11 more...)
|
| 46 |
NCT00529308 |
Completed
Has Results |
Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome |
|
- Device: Transcranial Magnetic Stimulation (active)
- Device: Transcranial Magnetic Stimulation (sham)
|
Interventional |
Phase 2 |
- Yale University
- Tourette Association of America
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Yale Global Tic Severity Scale (Y-GTSS)
- Motor Cortex Excitability Normalization-Right Motor Threshold
- Number of Patients With "Much Improved or Very Much Improved" on Clinical Global Impression-Improvement (CGI) Scale
- (and 2 more...)
|
20 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00529308 |
5480 |
TMS |
July 2007 |
July 2011 |
July 2011 |
September 14, 2007 |
August 26, 2015 |
February 15, 2013 |
- Yale University School of Medicine
New Haven, Connecticut, United States - New York State Psychiatric Institute
New York, New York, United States
|
| 47 |
NCT01904773 |
Completed
Has Results |
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder |
|
- Drug: AZD5213 and placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Total Tic Severity Score (Part 2 Only) Crossover Analysis Over 6 Periods
- Pharmacokinetics : Maximum Plasma Concentration (ng/ml) - Part 1 Only
- Pharmacokinetics : Time to Maximum Concentration (hr) - Part 1 Only
- Pharmacokinetics : AUC (h*ng/ ml) - Part 1 Only
|
29 |
All |
12 Years to 17 Years (Child) |
NCT01904773 |
D3032C00001 |
|
August 2013 |
February 2015 |
February 2015 |
July 22, 2013 |
September 23, 2016 |
July 25, 2016 |
- Research Site
Orange, California, United States - Research Site
St. Petersburg, Florida, United States - Research Site
Summit, New Jersey, United States - (and 4 more...)
|
| 48 |
NCT01329198 |
Active, not recruiting
Has Results |
Brain Stimulation for the Treatment of Tourette Syndrome |
|
- Device: NeuroPace RNS® (responsive neurostimulation) System Deep Brain Stimulator
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean Change in Yale Global Tic Severity Scale (YGTSS) Scores From Baseline to 6 Months Across All Study Participants Presented
- Correlation of Tics and Neural Physiology
|
5 |
All |
25 Years and older (Adult, Senior) |
NCT01329198 |
414-2008 |
|
September 2009 |
November 2011 |
November 2017 |
April 5, 2011 |
November 23, 2016 |
May 9, 2014 |
- University of Florida Movement Disorders Center
Gainesville, Florida, United States
|
| 49 |
NCT03058562 |
Completed |
A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome |
- Tourette Syndrome
- Chronic Motor Tic Disorder
|
- Drug: ABX-1431
- Drug: Placebo Comparator
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change of rating in Modified Rush Video Scale (MRVS) over time
- Change in rating of Yale Global Tic Severity Scale (YGTSS) over time
- Change of rating in Adult Tic Questionnaire (ATQ) over time
- (and 7 more...)
|
23 |
All |
18 Years to 65 Years (Adult) |
NCT03058562 |
ABX-1431_PN015 |
|
February 1, 2017 |
October 4, 2017 |
October 4, 2017 |
February 23, 2017 |
November 6, 2017 |
|
- Medizinische Hochschule Hannover
Hannover, Niedersachsen, Germany
|
| 50 |
NCT00034398 |
Completed |
Study of GABA-A Receptors in the Generation of Tics in Patients With Tourette's Syndrome |
|
|
Observational |
|
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
26 |
All |
18 Years to 65 Years (Adult) |
NCT00034398 |
020181
02-N-0181 |
|
April 24, 2002 |
|
March 11, 2010 |
April 29, 2002 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
Create an RSS feed from your search for:
Download the search results for: